Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.59 |
| ▸ | NOD1 | Q9Y239 | 14/20 | 0.56 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.55 |
| ▸ | BHMT | Q93088 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1158162 | 1.00 | PTGS1 (0.59) | PTGS1GSTK1NOD1GLO1BHMT | |
| SCHEMBL11870407 | 1.00 | PTGS1 (0.59) | PTGS1GSTK1NOD1GLO1BHMT | |
| SCHEMBL6927655 | 1.00 | PTGS1 (0.59) | PTGS1GSTK1NOD1GLO1BHMT | |
| SCHEMBL11870393 | 1.00 | PTGS1 (0.59) | PTGS1GSTK1NOD1GLO1BHMT | |
| SCHEMBL11866992 | 1.00 | PTGS1 (0.59) | PTGS1GSTK1NOD1GLO1BHMT | |
| SCHEMBL17075565 | 1.00 | PTGS1 (0.59) | PTGS1GSTK1NOD1GLO1BHMT | |
| SCHEMBL17075566 | 1.00 | PTGS1 (0.59) | PTGS1GSTK1NOD1GLO1BHMT | |
| SCHEMBL2091563 | 1.00 | PTGS1 (0.59) | PTGS1GSTK1NOD1GLO1BHMT | |
| SCHEMBL2091575 | 1.00 | PTGS1 (0.59) | PTGS1GSTK1NOD1GLO1BHMT | |
| SCHEMBL11872484 | 1.00 | PTGS1 (0.59) | PTGS1GSTK1NOD1GLO1BHMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363584-A1 | TREATMENT OF DANDRUFF | UNILEVER PLC (GB) | 2003-11-26 | — | — | EP | disclosed |
| US-20020168327-A1 | Treatment of dandruff | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2002-11-14 | — | — | US | disclosed |
| US-6451341-B1 | ADMINISTERING TO ANIMAL DIETARY SUPPLEMENT COMPRISING BUTYLATED HYDROXYTOLUENE(BHT), BUTYLATED HYDROXYANISOLE(BHA), VITAMIN E, AND B-CAROTENE TO PREVENT SKIN CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2002-09-17 | — | — | US | disclosed |
| WO-2002067880-A1 | TREATMENT OF DANDRUFF | UNILEVER PLC (GB) | 2002-09-06 | — | — | WO | disclosed |
| EP-0514451-B1 | DIETARY SUPPLEMENTS COMPRISING VITAMINS AND MINERALS | LIFESCIENCE CORP (US) | 1997-01-15 | — | — | EP | disclosed |
| US-5472698-A | Mixture of (N-acetyl)-L-serine, N-acetylcysteine and alpha-lipoic acid which promotes ceramide production in skin cells | ELIZABETH ARDEN CO., DIVISION OF CONOPCO, INC. (US) | 1995-12-05 | — | — | US | disclosed |
| EP-0514451-A1 | DIETARY SUPPLEMENTS COMPRISING VITAMINS AND MINERALS. | UNIV TEXAS (US) | 1992-11-25 | — | — | EP | disclosed |
| WO-1991011117-A2 | DIETARY SUPPLEMENTS COMPRISING VITAMINS AND MINERALS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1991-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020168327-A1 | Treatment of dandruff | CYP51A1, ERG28, SREBF1 | PTGS1 2480/4885GSTK1 1223/4885NOD1 3448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.